Major trial tests new drug combo to control aggressive blood cancer
NCT ID NCT06932562
Summary
This large, late-stage study is testing whether adding an experimental drug called linvoseltamab to a standard treatment regimen works better for controlling multiple myeloma. It will involve 1,000 adults newly diagnosed with this blood cancer who are not candidates for a stem cell transplant. Researchers will compare the new combination to the current standard treatment to see if it more effectively keeps the cancer in check and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
A.O.U. Careggi
RECRUITINGFlorence, Italy
Contact
-
AOU Ospedali Riuniti di Ancona
RECRUITINGAncona, Italy
Contact
-
Aarhus Universitetshospital
RECRUITINGAarhus, Denmark
Contact
-
Austin Hospital
RECRUITINGHeidelberg, Australia
Contact
-
Azienda USL IRCCS Di Reggio Emilia
RECRUITINGReggio, Italy
Contact
-
CHUC
RECRUITINGCoimbra, Portugal
Contact
-
Ege University Medicine Faculty, Izmir
RECRUITINGIzmir, Turkey (Türkiye)
Contact
-
Erasmus MC
RECRUITINGRotterdam, Netherlands
Contact
-
Fakultni Nemocnice Hradec Kralove
RECRUITINGHradec Králové, Czechia
Contact
-
Fakultni Nemocnice Ostrava
RECRUITINGOstrava, Czechia
Contact
-
Fakultni Nemocnice Plzen
RECRUITINGPilsen, Czechia
Contact
-
Hospital Clinic De Barcelona - Myeloma and Amyloidosis Unit
RECRUITINGBarcelona, Spain
Contact
-
Hospital Quirón Salud Madrid
RECRUITINGMadrid, Spain
Contact
-
Hospital Universitario Marques De Valdecilla -Hematology and Hemotherapy Service
RECRUITINGSantander, Spain
Contact
-
Hospital Universitario la Fe, Valencia
RECRUITINGValencia, Spain
Contact
-
Hospital da Luz Lisboa
RECRUITINGLisbon, Portugal
Contact
-
I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
RECRUITINGSan Giovanni Rotondo, Italy
Contact
-
IRCCS Ospedale Policlinico San Martino
RECRUITINGGenova, Italy
Contact
-
Kantonsspital St. Gallen
RECRUITINGSankt Gallen, Switzerland
Contact
-
Kuopio University Hospital
RECRUITINGKuopio, Finland
Contact
-
Meldola-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
RECRUITINGMeldola, Italy
Contact
-
Nepean Cancer Centre
RECRUITINGKingswood, Australia
Contact
-
North Estonia Medical Centre Foundation
RECRUITINGTallinn, Estonia
Contact
-
Ordensklinikum Linz
RECRUITINGLinz, Austria
Contact
-
Ospedale "Infermi" di Rimini
RECRUITINGRimini, Italy
Contact
-
St. Olavs hospital HF
RECRUITINGTrondheim, Norway
Contact
-
Stavanger University Hospital
RECRUITINGStavanger, Norway
Contact
-
Sunshine Coast Health
RECRUITINGSunshine Coast, Australia
Contact
-
Tartu University Hospital
RECRUITINGTartu, Estonia
Contact
-
Universitaetsspital Basel - Zentrum fur Hamato-Onkologie
RECRUITINGBasel, Switzerland
Contact
-
University Hospital Olomouc
RECRUITINGOlomouc, Czechia
Contact
-
University Hospital of Würzburg
RECRUITINGWürzburg, Germany
Contact
-
Vestfold Hospital Trust
RECRUITINGTønsberg, Norway
Contact
Conditions
Explore the condition pages connected to this study.